GENERIC PHARMASEC LIMITED

(Formerly known as Adi Rasayan Limited)

Registered Office: D/1105, Titanium City Center, Near. Sachin Tower, 100ft, Anandnagar Road, Satellite, Ahmedabad, Gujarat, 380015 Telephone: 8655550242

Website: www.genericpharmasec.in Email Id: genericpharmasec09@gmail.com

CIN: L24231GJ1992PLC018572

Date: 14/02/2019

To,
Department of Corporate Services, **BSE LIMITED**P. J. Towers, Dalal Street,
Mumbai - 400 001.

Dear Sir/ Madam,

Subject: Outcome of Board Meeting held on Thursday, 14th February, 2019.

Ref: BSE Scrip Code: 531592

Securities and Exchange Pursuant to Regulation 33 read with Regulation 30 of the Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you good self that the Board of Directors of the Company in their meeting held today at its Corporate Office has:

1. Considered and approved the Un-Audited Financial Results along with Limited Review Report for the Quarter ended on December 31st, 2018 pursuant to Regulation 33 of Listing Obligation and Disclosure Requirement, 2015.

Kindly take the same on your records.

Thanking You,

Yours Truly,

For Generic Pharmasec Limited (Formerly Known as Adi Rasayan Limited)

Viral Mehta Director

Din: 07927632

Resuyan III.

Encl: A/a

GENERIC PHARMASEC LIMITED

(Formerly known as Adi Rasayan Limited)

Statement of Standalone Unaudited Results for the Quarter and Period Ended 31st December, 2018

(Rs. In Lakhs)

-	Standalone Quarter Ended To The Period Ended						Year Ended
	Particulars						
Paruculars		31/12/2018 (Unaudited)	30/09/2018 (Unaudited)	31/12/2017 (Unaudited)	31/12/2018 (Unaudited)	31/12/2017 (Unaudited)	31/03/2018 (Audited)
1	Revenue from Operations	18.38	19.14		37.51	8.15	8.15
2	Other Income	15.26	12.11		15.27	0.15	9.01
3	Total Revenue (1 + 2)	33.64	19.14		52.78	8.15	17.16
4	Expenses Cost of materials consumed	-				-	-
	Purchase of stock-in-trade Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	*				*
	Employee benefits expense	0.42	0.41	0.49	1.27	0.99	1.61
	Depreciation and amortisation expense	0.01	0.01	0.01	0.02	0.02	0.02
	Other expenses	29.97	2.78	1.44	34.59	7.36	9.10
	Total expenses	30.40	3.19	1.94	35.88	8.37	10.74
5	Profit/(Loss) Before Exceptional item and Tax (3-4)	3.24	15.95	(1.94)	16.90	(0.22)	6.42
6	Exceptional items	-	-	-	-	-	-
7	Profit/(Loss) Before Tax (5-6)	3.24	15.95	(1.94)	16.90	(0.22)	6.42
8	Tax expense (1) Current Tax (2) Deferred Tax	0.61	2.61	:	3.22		1.22
9	Profit / (Loss) from continuing operations (7 - 8)	2.62	13.34	(1.94)	13.68	(0.22)	5.21
10	Profit / (Loss) from discontinuing operations						4
11	Tax expense of discontinuing operations		-				
12	Profit/(loss) from Discontinuing operations (after tax)						
13	Profit (Loss) for the period (9+12)	2.62	13.34	(1.94)	13.68	(0.22)	5.21
14	Other Comprehensive income; A (i) Items that will not be reclassified to profit or loss	2.10			2.10		
	(ii) Income tax relating to items that will not be reclassified to profit or loss B (i) Items that will be reclassified to	(0.54)			(0.54)		
	profit or loss (ii) Income tax relating to items that					.	
	will be reclassified to profit or loss	-					-
15	Total Comprehensive Income for the period (13+14) (Comprising profit/ (loss) and other Comprehensive Income for the period						
		4.17	13.34	(1.94)	15.23	(0.22)	5.21
16	Earnings per equity share (for discontinued & continuing operations) of face value of Rs. 10 each						
	(a) Basic (b) Diluted	0.12 0.04	4.09 4.09	(0.60) (0.60)	0.44 0.15	(0.07) (0.07)	1.60 1.60

Notes:

- 1 The above result were reviewed by the Audit Committee and approved by the Board Of directors at their meeting on 14th February, 2019.
- 2 The above result have been prepared in accordace with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), prescribed under section 133 of the Companies Act 2013, and other recognized accounting practices and policies to the extent applicable.
- 3 The Financial results for the quarter ended on 31st Dec, 2018 have been subjected to a "Limited Review" by the statutory auditors of the Company. The Limited review report does not contain any qualification. The Limited review report will be filed with the stock Exchange and will also be available on Company's website www.adirasyan.in
- 4 Previous period figures have been regrouped/reclassified as considered ncessary to facilitate comparison.
- 5 During the period under review the Board Directors of the Company at their meeting have approved the issue and allotment of 2,03,60,000 fully paid-up Equity Shares of Rs. 10/- each and 70,00,000 warrants Convertible in to 70,00,000 Equity shares of Rs. 10/- each fully paid on preferential allotment basis.

 Thus the EPS figure of quarter ended 31.12.2018 and year to date 31.12.2018 is non- comparable with other EPS figures.
- 6 The name has been changed from Adi Rasayan Limited to Generic Pharmasec Limited w.e.f. 27th November, 2018.

For and on behalf of the Board of GENERIC PHARMASEC LIMITED Formerly known as Adi Rasayan Limited

(VIRAL PANKAJ MEHTA) DIRECTOR DIN: 07927632

PLACE: MUMBAI





Roshal & associates chartered accountants

To Board of Directors of

Generic Pharmasec Limited (Formerly Known as "Adi Rasayan Limited") D/1105, Titanium City Center. Nr. Sachin Tower, 100ft, Anandnagar Road, Satellite, Ahmedabad 380015

We have reviewed the accompanying statement of unaudited financial results of Generic Pharmasec Ltd (Formerly known as "Adi Rasayan Limited") for the quarter ended 31st December, 2018 and the year to date results for the period from 1 April, 2018 to 31st December, 2018 attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

The preparation of the statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013, read with Rule 3 of Companies (Indian Accounting Standards) Rule, 2015, as amended, read with the Circular, is the responsibility of the Company's Management and has been approved by the Board of Directors of the Company. Our responsibility is to express a conclusion on the statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. Indian accounting Standards ('Ind AS') prescribed under s.133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For KOSHAL & ASSOCIATES Chartered Accountants Firm Reg.No.121233W

> Maheshwari Proprietor M.No.043746

Place of signature: Mumbai

Date: 14.02.2019